



Uric Acid Lowering Effect of Losartan in Patients with Stage 1 Hypertension and Asymptomatic Hyperuricemia

Thet PS, et al. Int. J. Sci. Res. 2024; 14 (1): 255-259

- Hyperuricemia and hypertension generally coexist and antihypertensive agents are commonly prescribed to individuals with these conditions together.
- Losartan has demonstrated both an antihypertensive as well as an antihyperuricemic effect, indicating a dual therapeutic advantage.
- The study initially administered Losartan at 25 mg daily for 4 weeks, followed by an increase to 50 mg daily for the next 4 weeks, in male patients with newly diagnosed stage 1 hypertension with asymptomatic hyperuricemia.
- Both doses significantly reduced blood pressure, however at 4 weeks, Losartan 50 mg demonstrated a substantial reduction (6.52%, $p=0.004$) of serum uric acid levels compared to the 25 mg dose (1.82% reduction), indicating a dose-dependent uric acid lowering effect.

Losartan is an effective uric acid lowering agent in newly diagnosed stage 1 hypertensive male patients with asymptomatic hyperuricemia.

